Skip to content
Meta-analysis Open access

Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy

Sep 2026 · Frontiers in Endocrinology · Vol 17 · 0 citations · 44 references
Medicine

TL;DR

Dose-response analysis showed that ecnoglutide exhibited a clear dose-dependent relationship for HbA1c, FPG, and body weight at doses ranging from 0.4 to 1.2 mg, while PPG was less affected by dose.

Abstract

Background Ecnoglutide, a novel long-acting GLP-1 receptor agonist, is considered a promising therapeutic option for the treatment of diabetes. This study aims to evaluate the efficacy and safety of ecnoglutide in adults with type 2 diabetes and to further investigate its dose-time relationship. Methods This study followed the PRISMA guidelines and systematically searched PubMed, Web of Science, Embase, and Cochrane Library, with the search updated through February 2026. Randomized controlled trials comparing ecnoglutide with placebo or the active control, dulaglutide, were included. The primary outcome was the change in HbA1c (%). Secondary outcomes included FPG, PPG, 7-point SMBG, body weight, adverse events, and serious adverse events. Risk of bias was assessed using the Cochrane RoB-2 tool. Meta-analyses employed a random-effects model, and mean differences and risk ratios were calculated with 95% confidence intervals. Results Three randomized controlled trials involving 977 participants were included. Compared with placebo, ecnoglutide significantly reduced HbA1c (MD = −1.40, 95% CI −1.65, −1.14, p < 0.00001), FPG (MD = −1.98, 95% CI −2.34, −1.63, p < 0.00001), PPG (MD = −4.88, 95% CI −6.32, −3.44, p < 0.00001), and body weight (MD = −2.16, 95% CI −2.62, −1.71, p < 0.00001). Additionally, compared with the placebo group, the incidence of adverse events was higher in the ecnoglutide group (OR = 2.03, 95% CI 1.24–3.32, p = 0.005), while there was no significant difference in the incidence of serious adverse events. Dose-response analysis showed that ecnoglutide exhibited a clear dose-dependent relationship for HbA1c, FPG, and body weight at doses ranging from 0.4 to 1.2 mg, while PPG was less affected by dose. Time-response analysis indicated that the hypoglycemic efficacy of ecnoglutide peaked around week 35 and subsequently plateaued, whereas body weight exhibited a sustained linear downward trend. Conclusion Ecnoglutide significantly improved glycemic control and reduced body weight, although it was associated with a higher incidence of adverse events without increasing serious adverse events. Despite these promising findings, the evidence remains limited and requires confirmation in larger, multicenter randomized controlled trials. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261327235, identifier CRD420261327235.

Read PDF

Similar papers

Review Open access Oct 2026

Efficacy and Safety of Remogliflozin in Adults with Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis

Introduction: Remogliflozin is a sodium–glucose cotransporter-2 inhibitor used for type 2 diabetes mellitus (T2DM), but its overall efficacy and safety remain fragmented. This updated systematic review and meta-analysis evaluated the efficacy and safety of remogliflozin using evidence exclusively from randomized contro...

N. Kostadinov, T. Totomirova, Z. Kirovakov et al. · 0 citations
Review Open access Oct 2026

Cardiovascular effects of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

The efficacy of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, in improving metabolic parameters is well established in patients with type 2 diabetes and obesity. However, despite its rapidly expanding clinical use, the overall cardiova...

M. Saffi, M. Clemente, L. D. Cancela Goncalves et al. · 0 citations
Review Sep 2026

Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment.

Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 that reduces LDL-C and increases apolipoprotein A1 and high-density lipoprotein cholesterol and increased apolipoprotein A1 and high-density lipoprotein cholesterol (all P < 0.0001).

Ahmed Talkhan, M. Elkasaby, Ahmed S. A. Osman et al. · 0 citations
Review Open access Oct 2026

Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.

CagriSema provides substantial glycaemic and body-weight benefits versus placebo and is more evident for body-weight reduction, while comparative gastrointestinal tolerability and discontinuation risk remain uncertain.

C. S. Kow, A. F. Zaihan, D. Ramachandram et al. · 0 citations
Review Open access Aug 2026

Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

Background Type 2 diabetes mellitus (T2DM) remains a major global health burden. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide improve glycemic control and promote weight loss, many patients do not achieve optimal metabolic targets. Mazdutide, a dual GLP-1 and glucagon receptor agoni...

Ahmad Hassan, Qurrat Ul Ain Farooq, Fnu Parwesh et al. · 0 citations
Review Open access Sep 2026

The Efficacy and Safety of Etrasimod for the Induction and Maintenance of Remission in Moderate to Severe Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials

The findings of this meta-analysis support Etrasimod as an effective and well-tolerated treatment option for achieving and maintaining remission in patients with moderate to severe UC.

Ch. Zaid Riaz, M. Raza, Iman Afraz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.